Last reviewed · How we verify
NCT06639516
Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial
NA trial testing Bifidobacterium longum in Acute Pancreatitis in 60 participants. Not yet recruiting.
1 December 2025
Quick facts
| Lead sponsor | The First Affiliated Hospital of Nanchang University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 15 February 2025 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Bifidobacterium longum
- Placebo
- Standard clinical treatment
Conditions studied
- Acute Pancreatitis — all drugs for Acute Pancreatitis →
Sponsor
The First Affiliated Hospital of Nanchang University
Who can join
Adults 18 to 75, any sex, with Acute Pancreatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical trial is to investigate the impact of Bifidobacterium longum(BL) on the clinical prognosis of patients with acute pancreatitis(AP), to analyze the correlation between BL and intestinal barrier function, as well as the gut microbiota, and to observe adverse reactions and risks in patients with AP after the use of BL. Participants will be randomly assigned to two groups: the intervention group and the control group. They will receive: * Intervention group: Standard clinical treatment + BL capsules (10\^10 CFU), twice a day, for a total of 14 days; * Control group: Standard clinical treatment + placebo capsules, for a total of 14 days. A total of 60 patients will be included in this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06639516
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bifidobacterium longum
Trials testing the same drug.
- NCT07420231 — Evaluation of the Synergistic Effect of Combining a Prebiotic and a Postbiotic on Intestinal Discomfort · NA · not yet recruiting
- NCT05054309 — A Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects W · NA · completed
- NCT04911556 — the Effect of Probiotics on Aging Population · NA · unknown
- NCT04042181 — The Effects of Supplementation of a Probiotic, B. Longum, on BMI and Anthropometric Outcomes in Overweight/Obese Adults. · NA · unknown
- NCT03056846 — Probiotics on Stress-associated Gastrointestinal Function in University Students · NA · completed
Other recruiting trials for Acute Pancreatitis
Currently open trials in the same condition.
- NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
- NCT06899087 — DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis · recruiting
- NCT07322978 — Incidence of Splanchnic Venous Thrombosis in Acute Pancreatitis and it's Correlation With Severity of Pancreatitis · recruiting
- NCT03547232 — Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial) · Phase 4 · recruiting
- NCT06401577 — Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics · recruiting
Other The First Affiliated Hospital of Nanchang University trials
Trials by the same sponsor.
- NCT07136961 — Efficacy and Safety of Robotic-assisted Bronchoscopy Combined With the ICNVA Strategy in Biopsy of Peripheral Pulmonary · NA · active not recruiting
- NCT06999031 — A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
- NCT06752057 — Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment · NA · recruiting
- NCT06751966 — Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment · NA · recruiting
- NCT06752044 — Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatm · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06639516 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Nanchang University
- Last refreshed: 6 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06639516.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing